Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of €2,650.0 Million And Losses?
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 24,000 Shares of Stock
Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?
BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
BioNTech (NASDAQ: BNTX) CEO sells 93,000 shares under preplanned deal - Markets Daily
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 72,000 Shares
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 72,000 Shares of Company Stock - Stock Observer
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $126.00 According to Brokerages - Markets Daily
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Consensus Target Price of $126.00
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 17,000 Shares
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
BioNTech (NASDAQ:BNTX) CEO Sells $2,664,630.00 in Stock - Markets Daily
BioNTech (NASDAQ:BNTX) CEO Sells $3,347,980.00 in Stock - Stock Observer
BioNTech CEO sold shares under plan - Stock Observer
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 32,000 Shares of Stock
BioNTech Closes Manufacturing Sites in Germany and Singapore Amidst Failed Sales, ETPharma
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 34,000 Shares
How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)
BioNTech (NasdaqGS:BNTX) Stock May Look Fully Valued On Fresh Lung Cancer Trial Data
BioNTech co-founders name new pharmaceutical company 'Arife' - Türkiye News
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 30,000 Shares
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 39,000 Shares - Stock Observer
BioNTech (NASDAQ:BNTX) CEO Sells 46,000 Shares of Stock
Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,633,120.00 in Stock - Zolmax
BioNTech (NASDAQ:BNTX) CEO Sells 33,000 Shares
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Biontech Se (BNTX) - Insider Monkey
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
BioNTech (BNTX) Could Be 19% Undervalued On Vaccine Approval And Phase 3 Data
Ugur Sahin Sells 34,000 Shares of BioNTech (NASDAQ:BNTX) Stock
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 30,000 Shares - Daily Political
Did Survival Trial Win Just Shift BioNTech (BNTX) Investment Narrative?
Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?
BioNTech (NASDAQ:BNTX) CEO Sells $3,280,660.00 in Stock
Ugur Sahin Sells 15,000 Shares of BioNTech (NASDAQ:BNTX) Stock
BioNTech (NASDAQ:BNTX) CEO Sells 34,000 Shares of Stock - Stock Observer
BioNTech's Lung Cancer Drug Shows Signs of a Major Breakthrough
BioNTech and OncoC4 report median OS data from RESERVE-003 Phase III trial
Brokerages Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $127.44 - Zolmax
Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,361,850.00 in Stock
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 41,000 Shares of Stock - Stock Observer
BioNTech (NASDAQ:BNTX) Shares Gap Up - What's Next?
BioNTech lung cancer drug extends survival versus chemotherapy
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) PT at $127.44 - Daily Political
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $127.44 - Markets Daily
Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells 36,000 Shares of Stock - Markets Daily
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 37,000 Shares
BioNTech (NASDAQ:BNTX) CEO Sells $3,520,080.00 in Stock - Stock Observer
New MUC16-targeting ADC reported in Biontech patent
BioNTech SE Sponsored ADR $BNTX Shares Sold by Carmignac Gestion
Ugur Sahin Sells 31,500 Shares of BioNTech (NASDAQ:BNTX) Stock - Zolmax
Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells 31,500 Shares of Stock - Markets Daily
Carmignac Gestion Has $7.45 Million Stake in BioNTech SE Sponsored ADR $BNTX - Daily Political
BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts
BioNTech Shares Fall After BMO Downgrade and Price Target Cut
